Disease · MONDO_0005654
ascariasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ascariasis. Diseases, record MONDO_0005654. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005654
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Ascariasis - roundworm, Ascaris lumbricoides caused disease or disorder, Ascaris lumbricoides disease or disorder, Ascaris lumbricoides infectious disease
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PIPERAZINE | CHEMBL1412 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ALBENDAZOLE | CHEMBL1483 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| IVERMECTIN | CHEMBL6067487 | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets | |
| MEBENDAZOLE | CHEMBL685 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MOXIDECTIN | CHEMBL2104415 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXFENDAZOLE | CHEMBL42442 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03527732 | Efficacy and Safety of IVM/ALB Co-administration | Phase 2/3 | 1,673 | 2024-03-20 | Trichuriasis | ALBENDAZOLE, IVERMECTIN | Its record names the disease | ClinicalTrials.gov |
| NCT04700423 | Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration | Phase 2/3 | 536 | 2024-12-05 | Trichuriasis, Ascariasis, Hookworm Infections, Helminthes; Infestation, Intestinal | ALBENDAZOLE, IVERMECTIN, MOXIDECTIN | Its record names the disease | ClinicalTrials.gov |
| NCT02034162 | A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants | Phase 3 | 295 | 2016-11-04 | Helminth Infections | MEBENDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04177654 | Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs | 9,457 | Soil-transmitted Helminth Infections | ALBENDAZOLE, MEBENDAZOLE | Its record names the disease | ClinicalTrials.gov | ||
| NCT02420574 | Assessment of Drug Efficacy of Local Albendazole | Not applicable | 679 | Helminthiasis | ALBENDAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00207753 | Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections | Not applicable | 550 | Ascariasis, Trichuriasis, Hookworm Infection, Strongyloidiasis, Pediculosis | ALBENDAZOLE, IVERMECTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06037876 | Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura | Phase 3 | 161 | Trichuriasis | ALBENDAZOLE, IVERMECTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07045493 | Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh | Phase 2 | 110 | Soil Transmitted Helminth (STH) Infections | ALBENDAZOLE, IVERMECTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03435718 | Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults | Phase 2 | 0 | Trichuris Infection | ALBENDAZOLE, OXFENDAZOLE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Double-blind Mebendazole 500 mg vs Double-blind Placebo: Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period | 9 of 144 | 8 of 140 | 284 | NCT02034162 |
Source Trial comparisons
Papers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005654
GET https://conductscience.org/api/diseases/v1/MONDO_0005654/papers?page=2